Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03052530
Other study ID # VP-0714
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 5, 2017
Est. completion date July 24, 2017

Study information

Verified date April 2018
Source OrbusNeich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during percutaneous coronary intervention.

Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters 1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date July 24, 2017
Est. primary completion date July 24, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Clinical Inclusion Criteria:

1. Subject is = 18 years of age.

2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.

3. Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.

4. Subjects must have a single or double vessel coronary artery disease and clinical evidence of ischemic heart disease, such as stable / unstable angina or silent ischemia.

Angiographic Inclusion Criteria

5. Subject must have de novo or restenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention. An embolic protection device must be used in all Saphenous venous grafts (SVG) interventions performed during the index procedure.

6. A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.

7. Target and non-target lesions must be located in different coronary arteries or bypass grafts.

8. Target lesion(s) must have a diameter stenosis of =70% by visual estimation and may include chronic total occlusions (CTO)

9. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success.

Clinical Exclusion Criteria:

1. Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.

2. Subject with known diagnosis of an acute myocardial infarction (AMI) within 72 hours prior to index procedure.

3. Subject with known pregnancy or is nursing. Women of child- bearing potential should have a documented negative pregnancy test within 7 days before index procedure.

4. Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.

5. A serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.

6. Cerebrovascular accident (CVA) within the past 6 months.

7. Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.

8. Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary)

Angiographic Exclusion Criteria

9. More than two lesions requiring treatment.

10. Unprotected left main coronary artery disease.(Greater than 50% diameter stenosis)

11. Coronary artery spasm of the target vessel in the absence of a significant stenosis.

12. Target lesion with angiographic presence of probable or definite thrombus.

13. Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.

14. Non-target lesion to be treated during the index procedure meets any of the following criteria:

- Located within a bypass graft (venous or arterial)

- Left main location

- Chronic total occlusion

- Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)

- Treatment not deemed a clinical angiographic success

Study Design


Intervention

Device:
Sapphire II PRO
To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.

Locations

Country Name City State
United States Piedmont Heart Institute Atlanta Georgia
United States The Christ Hospital Heart and Vascular Cincinnati Ohio
United States University of Miami Miami Florida
United States Peninsula Regional Medical Center Salisbury Maryland

Sponsors (2)

Lead Sponsor Collaborator
OrbusNeich Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Device Procedural Success Device procedural success consisting of the following:
Successful delivery, inflation, deflation and withdrawal of the study balloon
No evidence of vessel perforation, flow limiting dissection (grade C or higher) or reduction in TIMI flow from baseline related to the study balloon
Final TIMI flow grade of 3 at the conclusion of the PCI procedure
Peri-procedural (at Day 0)
Secondary Number of Participants With In-hospital Major Adverse Cardiac Events (MACE) In-hospital Major Adverse Cardiac Events (MACE)
All death (cardiac and non-cardiac)
Myocardial infarction (MI)
Target Lesion Revascularization (TLR)
Endpoints will be measured through hospital discharge (expected to be within 24 hours)
Secondary Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel In-hospital stent thrombosis (ST) within the target vessel Endpoint will be measured through hospital discharge (expected to be within 24 hours)
Secondary Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention) Clinically Significant Arrhythmias (requiring intervention) Endpoint will be measured through hospital discharge (expected to be within 24 hours)
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A